Initial combination of empagliflozin and linagliptin in subjects with type 2 diabetes

Diabetes Care

Volumn 38, Issue 3, 2015, Pages 394-402

  Lewin, Andrew ^a   DeFronzo, Ralph A ^b   Patel, Sanjay ^c   Liu, Dacheng ^d   Kaste, Renee ^d   Woerle, Hans J ^e   Broedl, Uli C ^e  

^a NATIONAL RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c BOEHRINGER INGELHEIM LTD   (United Kingdom)

^d BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; HEMOGLOBIN A1C; LINAGLIPTIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLUCOSE BLOOD LEVEL; GLUCOSIDE; GLYCOSYLATED HEMOGLOBIN; PURINE DERIVATIVE; QUINAZOLINE DERIVATIVE;

ADULT; ANALYSIS OF COVARIANCE; ANTIDIABETIC ACTIVITY; ARTHRALGIA; ARTICLE; BACKACHE; CLINICAL PROTOCOL; CONSTIPATION; CONTROLLED STUDY; DIET; DISEASE DURATION; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; GLOMERULUS FILTRATION RATE; GLUCOSE ABSORPTION; GOOD CLINICAL PRACTICE; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INFLUENZA; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; BLOOD; CLINICAL TRIAL; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; MIDDLE AGED; MULTICENTER STUDY; TREATMENT OUTCOME;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PURINES; QUINAZOLINES; TREATMENT OUTCOME;

EID: 84928199102     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc14-2365     Document Type: Article

References (21)

1. Grempler R, Thomas L, Eckhardt M, et al. Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 2012;14:83-90.
2. Heise T, Seewaldt-Becker E, Macha S, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab 2013; 15:613-621.
3. Roden M, Weng J, Eilbracht J, et al.; EMPAREG MONO trial investigators. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 2013; 1:208-219.
4. Roden M, Weng J, Merker L, et al. Empagliflozin monotherapy for $76 weeks in drug-näive patients with type 2 diabetes (Abstract). Diabetes 2014;63(Suppl. 1):A264.
5. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin- 1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin- 2-ylmethyl)-3, 7-dihydro-purine-2, 6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008;325:175-182.
6. Gallwitz B. Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes. Diabetes Metab Syndr Obes 2013;6:1-9.
7. DelPrato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA. Effect of linagliptin monotherapy on glycaemic control and markers of b-cell function in patients with inadequately controlled type 2 diabetes: A randomized controlled trial. Diabetes Obes Metab 2011;13:258-267.
8. Gomis R, Owens DR, Taskinen MR, et al. Long-term safety and efficacy of linagliptin as monotherapy or in combination with other oral glucose-lowering agents in 2121 subjects with type 2 diabetes: up to 2 years exposure in 24- week phase III trials followed by a 78-week openlabel extension. Int J Clin Pract 2012;66:731-740.
9. Inzucchi SE, Bergenstal RM, Buse JB, et al.; American Diabetes Association (ADA); European Association for the Study of Diabetes (EASD). Management of hyperglycemia in type 2 diabetes: A patient-centered approach: Position statement of the American DiabetesAssociation (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.
10. De Fronzo RA, Eldor R, Abdul-Ghani M. Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 2013;36(Suppl. 2):S127-S138.
11. Glucophage (metformin hydrochloride) tablets. Glucophage XR (metformin hydrochloride) extended-release tablets [package insert]. Princeton, NJ, Bristol-Myers Squibb Company, 2009.
12. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD; DARTS/MEMO Collaboration. Contraindications to metformin therapy in patients with type 2 diabetes-a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18: 483-488.
13. Holstein A, Nahrwold D, Hinze S, Egberts EH. Contra-indications to metformin therapy are largely disregarded.Diabet Med 1999;16:692-696.
14. Bouchoucha M, Uzzan B, Cohen R. Metformin and digestive disorders. Diabetes Metab 2011;37:90-96.
15. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27:1535-1540.
16. Barnett AH. Impact of sodium glucose cotransporter 2 inhibitors on weight in patients with type 2 diabetes mellitus. Postgrad Med 2013;125:92-100.
17. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: A systematic review and meta-analysis. J Am Soc Hypertens 2014;8: 262-275, e9.
18. Cherney DZ, Perkins BA, Soleymanlou N, et al. The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus. Cardiovasc Diabetol 2014;13:28.
19. Cherney DZ, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodiumglucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation 2014;129:587-597.
20. Johansen OE, Neubacher D, von Eynatten M, Patel S, Woerle HJ. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: A pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol 2012;11:3.
21. Ahŕen B. Avoiding hypoglycemia: A key to success for glucose-lowering therapy in type 2 diabetes. Vasc Health Risk Manag 2013;9:155-163.